<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852018000100001</article-id>
<article-id pub-id-type="doi">10.24245/revmexurol.v78i1.1458</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Repercusión de la diabetes tipo 2 en la clasificación TNM de pacientes con cáncer renal]]></article-title>
<article-title xml:lang="en"><![CDATA[Impact of type 2 diabetes mellitus on the TNM classification of kidney cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Uscanga-Yépez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Oyervides]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Olvera-Posada]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Góngora-Cortéz]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barrera Juárez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Metropolitano Dr. Bernardo Sepúlveda Departamento de Urología ]]></institution>
<addr-line><![CDATA[ Nuevo León]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Cirugía Centro Médico Zambrano Hellion ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Tecnológico de Estudios Superiores de Monterrey Departamento de Urología Escuela Nacional de Medicina]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<volume>78</volume>
<numero>1</numero>
<fpage>1</fpage>
<lpage>8</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852018000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852018000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852018000100001&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Analizar la repercusión de la diabetes tipo 2 en la clasificación TNM (estadificación) de pacientes con cáncer renal y nefrectomía.  Materiales y métodos:  Estudio transversal, retrospectivo y descriptivo, efectuado mediante la revisión de los expedientes de pacientes con carcinoma de células renales esporádico y unilateral, nefrectomía, atendidos entre 2008 y 2014 en el Departamento de Urología del Hospital Metropolitano Dr. Bernardo Sepúlveda. Variables demográficas y clínicas: edad, sexo, tamaño tumoral patológico y tipo de cirugía (radical o parcial); comorbilidades (hipertensión arterial sistémica, diabetes mellitus tipo 2 y dislipidemia); estadificación y tamaño del tumor (clasificación TNM 2009), grado de diferenciación celular y tipo histológico. Las características clínicas y patológicas se analizaron de forma independiente con la prueba c2. Los índices de supervivencia global y libre de recurrencia se analizaron con la prueba de Kaplan-Meier.  Resultados:  Se estudiaron 43 pacientes, 18.6% de ellos con diabetes tipo 2. Predominaron los tumores T1b en 32.6% de los casos. No se encontraron diferencias estadísticamente significativas al comparar el estadio tumoral patológico (p = 0.5), enfermedad ganglionar (p = 0.7) y metástasis (p = 0.5) en pacientes con y sin diabetes. La mediana de seguimiento fue de 45 meses, diferencias al comparar la supervivencia global y libre de recurrencia en pacientes con y sin diabetes tipo 2 (p = 0.76 y 0.78, respectivamente).  Conclusión:  La diabetes tipo 2 no repercute de forma significativa en el estadio patológico de pacientes con cáncer renal, ni en la supervivencia global ni libre de recurrencia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To evaluate the influence of type 2 diabetes mellitus on the TNM staging classification in patients with renal cell carcinoma treated through nephrectomy.  Materials and methods:  A retrospective, cross-sectional, descriptive study was conducted. The case records were reviewed of patients with sporadic and unilateral renal cell carcinoma that underwent nephrectomy at the Urology Department of the Hospital Metropolitano Dr. Bernardo Sepúlveda. Demographic and clinical variables: age, sex, pathologic tumor size, and type of surgery (radical or partial). The comorbidities evaluated were high blood pressure, type 2 diabetes mellitus, and dyslipidemia. Staging and tumor size (2009 TNM classification), Fuhrman grade, and histologic type were analyzed. Each TNM classification result was analyzed independently through the &#967;2 test. Overall survival and recurrence-free survival were evaluated through the Kaplan-Meier test.  Results:  A total of 18.6% of the 43 study patients presented with type 2 diabetes mellitus. T1b tumors predominated in 32.6% of the cases. No statistically significant differences were found in the comparison of pathologic tumor stage (p = 0.5), lymph node disease (p = 0.7), or metastasis (p = 0.5) between patients with and without diabetes. Median follow-up was 45 months and no differences were found in the comparison of overall survival and recurrence-free survival in the patients with type 2 diabetes mellitus (p = 0.76) and those without the pathology (p = 0.78).  Conclusions:  Type 2 diabetes mellitus had no significant impact on the pathologic stage of renal cell carcinoma or on overall survival and recurrence-free survival in those patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer renal]]></kwd>
<kwd lng="es"><![CDATA[clasificación TNM]]></kwd>
<kwd lng="es"><![CDATA[nefrectomía]]></kwd>
<kwd lng="es"><![CDATA[diabetes mellitus tipo 2]]></kwd>
<kwd lng="en"><![CDATA[Renal cell carcinoma]]></kwd>
<kwd lng="en"><![CDATA[TNM classification]]></kwd>
<kwd lng="en"><![CDATA[Nephrectomy]]></kwd>
<kwd lng="en"><![CDATA[Type 2 diabetes mellitus]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scosyrev]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Messing]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Noyes]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Veazie]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Messing]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: An overview]]></article-title>
<source><![CDATA[Urol Oncol Semin Orig Investig]]></source>
<year>2012</year>
<volume>30</volume>
<page-range>126-32</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>American Cancer Society</collab>
<source><![CDATA[Cancer Facts and Figures]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>SINAIS</collab>
<collab>SINAVE</collab>
<collab>DGE</collab>
<collab>SALUD</collab>
<source><![CDATA[Perfil epidemiológico de los tumores malignos en México]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navai]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Environmental and modifiable risk factors in renal cell carcinoma]]></article-title>
<source><![CDATA[Urol Oncol Semin Orig Investig]]></source>
<year>2012</year>
<volume>30</volume>
<page-range>220-4</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weikert]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ljungberg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary epidemiology of renal cell carcinoma: Perspectives of primary prevention]]></article-title>
<source><![CDATA[World J Urol]]></source>
<year>2010</year>
<volume>28</volume>
<page-range>247-52</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension and subsequent genitourinary and gynecologic cancers risk: a population-based cohort study]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2015</year>
<volume>94</volume>
<numero>16</numero>
<issue>16</issue>
<publisher-loc><![CDATA[Baltimore ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Gridley]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fraumeni]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Järvholm]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity, hypertension, and the risk of kidney cancer in men]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2000</year>
<volume>343</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1305-11</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zelenko]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes and cancer]]></article-title>
<source><![CDATA[Endocrinol Metab Clin North Am]]></source>
<year>2014</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>167-85</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of diabetes mellitus on renal cell carcinoma prognosis]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2015</year>
<volume>94</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1-8</page-range><publisher-loc><![CDATA[Baltimore ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Jeon]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Body mass index and survival in patients with renal cell carcinoma: A clinical-based cohort and meta-analysis]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2012</year>
<volume>132</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>625-34</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Kook]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Visceral obesity in predicting oncologic outcomes of localized renal cell carcinoma]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2014</year>
<volume>192</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1043-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Min]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Jeon]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy]]></article-title>
<source><![CDATA[Mol Clin Oncol]]></source>
<year>2013</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>365-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tseng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 Diabetes Mellitus and Kidney Cancer Risk : A Retrospective Cohort Analysis of the National Health Insurance]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Psutka]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Boorjian]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Lohse]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2014</year>
<volume>192</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1620-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Kwak]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic significance of diabetes mellitus in localized renal cell carcinoma]]></article-title>
<source><![CDATA[Jpn J Clin Oncol]]></source>
<year>2012</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>318-24</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hofner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zeier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hatiboglu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Eisen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of type 2 diabetes on the outcome of localized renal cell carcinoma]]></article-title>
<source><![CDATA[World J Urol]]></source>
<year>2014</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1537-42</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levey]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Coresh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2006</year>
<volume>145</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>247-54</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barone]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Peairs]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2008</year>
<volume>300</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2754-64</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fukushima]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Masuda]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yokoyama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tatokoro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma]]></article-title>
<source><![CDATA[Jpn J Clin Oncol]]></source>
<year>2013</year>
<volume>43</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>740-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ha]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Yun]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2013</year>
<volume>20</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3662-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antonelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arrighi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Corti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zanotelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: A single-center retrospective study]]></article-title>
<source><![CDATA[Urol Oncol]]></source>
<year>2012</year>
<volume>31</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1310-5</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giovannucci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2007</year>
<volume>132</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2208-25</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Renehan]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Frystyk]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Flyvbjerg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and cancer risk: the role of the insulin-IGF axis]]></article-title>
<source><![CDATA[Trends Endocrinol Metab]]></source>
<year>2006</year>
<volume>17</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>328-36</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosendahl]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Forsberg]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of IGF-IR stimulation or blockade on proliferation of human renal cell carcinoma cell lines]]></article-title>
<source><![CDATA[Int J Oncol]]></source>
<year>2004</year>
<volume>25</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1327-36</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosendahl]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Holly]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Celander]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Forsberg]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2008</year>
<volume>123</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1286-91</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Habib]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2014</year>
<volume>5</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2542-50</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larsson]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Wolk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes mellitus and incidence of kidney cancer : a meta-analysis of cohort studies]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2001</year>
<volume>54</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1013-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Denton]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[MAgee]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Ovuworie]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mauiyyedi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2002</year>
<volume>61</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2201-9</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of blood pressure in patients with type 2 diabetes mellitus: a nationwide survey in Korean]]></article-title>
<source><![CDATA[Diabetes Metab J]]></source>
<year>2011</year>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>348-53</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Salud Pu&#769;blica en México</collab>
<source><![CDATA[Encuesta Nacional en Salud y Nutrición]]></source>
<year>2012</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
